NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...

The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.

RA Capital Management, LP ("RA Capital"), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

COPENHAGEN, Sept 11 (Reuters) - Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side ...

Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...

Eli Lilly and Novo Nordisk currently lead this market, but smaller competitors such as Roche, Pfizer, Amgen, and Viking are ramping up their efforts in developing weight-loss treatments.